Matthew Biegler analyst OPPENHEIMER

Currently out of the existing stock ratings of Matthew Biegler, 74 are a BUY (92.5%), 6 are a HOLD (7.5%).

Matthew Biegler

Work Performance Price Targets & Ratings Chart

Analyst Matthew Biegler works at OPPENHEIMER with a stock forecast success ratio of 25.07% fulfilled within 51.82 days on average.

Matthew Biegler’s has documented 148 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on FULC, Fulcrum Therapeutics at 14-May-2024.

Wall Street Analyst Matthew Biegler

Analyst best performing recommendations are on CELU (CELULARITY).
The best stock recommendation documented was for CELU (CELULARITY) at 1/28/2022. The price target of $9 was fulfilled within 41 days with a profit of $4.74 (111.27%) receiving and performance score of 27.14.

Average potential price target upside

FATE Fate Therapeutics MRKR Marker Therapeutics TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals Llc BPMC Blueprint Medicines Corp FIXX Homology Medicines FULC Fulcrum Therapeutics NKTX Nkarta  VOR Vor Biopharma CELU Celularity MDNA Medicenna Therapeutics Corp TYRA Tyra Biosciences IDYA Ideaya Biosciences RLAY Relay Therapeutics  PRTG Portage Biotech APTO Aptose Biosciences OLMA Olema Pharmaceuticals DAWN Day One Biopharmaceuticals

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

4

$0.1 (2.56%)

12

8 days ago

18/23 (78.26%)

$-0.08 (-1.96%)

254

Buy

9

$5.1 (130.77%)

16

8 days ago

0/3 (0%)

$4.92 (120.59%)

Hold

6

$2.1 (53.85%)

7

8 days ago

3/7 (42.86%)

$1.92 (47.06%)

88

Hold

5

$1.1 (28.21%)

7

8 days ago

7/11 (63.64%)

$0.92 (22.55%)

153

Sell

6

$2.1 (53.85%)

4

1 months 20 days ago

2/3 (66.67%)

$-1.34 (-18.26%)

111

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Biegler is most bullish on?

Potential upside of $18.36 has been obtained for RLAY (RELAY THERAPEUTICS )

Which stock is Matthew Biegler is most reserved on?

Potential downside of -$0 has been obtained for FATE (FATE THERAPEUTICS)

What Year was the first public recommendation made by Matthew Biegler?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?